Apex Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Apex Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$42M	Buy	1,036,620 +16,524	+2%	+$671K	0.93%	44
2015 Q4	$63.2M	Buy	1,020,096 +478	+0%	+$25.8K	1.41%	17
2015 Q3	$41.2M	Buy	1,019,618 +39,489	+4%	+$2.04M	0.93%	43
2015 Q2	$56.4M	Buy	980,129 +51,475	+6%	+$3.27M	1.21%	33
2015 Q1	$59.1M	Buy	928,654 +41,135	+5%	+$2.79M	1.39%	22
2014 Q4	$54.8M	Buy	887,519 +43,728	+5%	+$2.16M	1.46%	21
2014 Q3	$32.8M	Sell	843,791 -45,754	-5%	-$1.62M	0.99%	43
2014 Q2	$30.6M	Buy	889,545 +174,228	+24%	+$5.49M	0.94%	48
2014 Q1	$30.9M	Sell	715,317 -42,593	-6%	-$2.06M	1.09%	38
2013 Q4	$30.2M	Buy	+757,910	New	+$27M	1.13%	37

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Apex Capital Management's IONS Position: Q1 2016 in Review

Apex Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 1.6% in Q1 2016, buying an estimated $671K and bringing the position to 1,036,620 shares worth $42M. The position accounts for 0.93% of the portfolio, ranked #44.

Apex Capital Management first reported a position in IONS in Q4 2013 and has held it in 10 quarters since. The position peaked at $63.2M in Q4 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

Apex Capital Management held 1,036,620 shares of Ionis Pharmaceuticals worth $42M as of Q1 2016.
Apex Capital Management bought 16,524 Ionis Pharmaceuticals shares in Q1 2016, an estimated $671K.
Ionis Pharmaceuticals made up 0.93% of Apex Capital Management's portfolio in Q1 2016, its #44 holding.
Apex Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2013 and has held it in 10 quarters since.
Apex Capital Management's Ionis Pharmaceuticals position peaked at $63.2M in Q4 2015.
314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.